During the last session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s traded shares were 1.54 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $2.37, reflecting an intraday gain of 0.85% or $0.02. The 52-week high for the MREO share is $5.02, that puts it down -111.81 from that peak though still a striking 5.06% gain since the share price plummeted to a 52-week low of $2.25. The company’s market capitalization is $366.71M, and the average intraday trading volume over the past 10 days was 0.74 million shares, and the average trade volume was 1.20 million shares over the past three months.
Mereo Biopharma Group Plc ADR (MREO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. MREO has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.03.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Mereo Biopharma Group Plc ADR (MREO) registered a 0.85% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.85% in intraday trading to $2.37, hitting a weekly high. The stock’s 5-day price performance is -8.14%, and it has moved by -5.95% in 30 days. Based on these gigs, the overall price performance for the year is -20.47%. The short interest in Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is 6.03 million shares and it means that shorts have 3.82 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.5, which implies an increase of 68.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $8 respectively. As a result, MREO is trading at a discount of -237.55% off the target high and -68.78% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 28.65M as predicted by 3 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 18.09M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.78%. While earnings are projected to return 35.71% in 2025.
MREO Dividends
Mereo Biopharma Group Plc ADR is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Mereo Biopharma Group Plc ADR insiders own 1.02% of total outstanding shares while institutional holders control 74.31%, with the float percentage being 75.07%. RUBRIC CAPITAL MANAGEMENT LP is the largest shareholder of the company, while 98.0 institutions own stock in it. As of 2024-06-30, the company held over 15.31 million shares (or 2.1506% of all shares), a total value of $55.11 million in shares.
The next largest institutional holding, with 11.79 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 1.6566% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.45 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mereo Biopharma Group Plc ADR (MREO) shares are Tema GLP-1, Obesity & Cardiometabolic ETF and Tema Oncology ETF . Data provided on Nov 30, 2024 indicates that Tema GLP-1, Obesity & Cardiometabolic ETF owns about 524.03 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $1.24 million market value. The same data shows that the other fund manager holds slightly less at 319.01, or about 0.01% of the stock, which is worth about $0.76 million.
